No Data
No Data
Guangdong VTR Bio-Tech Co., Ltd.'s (SZSE:300381) Largest Shareholders Are Retail Investors Who Were Rewarded as Market Cap Surged CN¥398m Last Week
Profit: Report for the third quarter of 2024
Guangdong VTR Bio-Tech (300381.SZ) released its performance for the first three quarters, with a net income of 42.7988 million yuan, an increase of 245.33%.
Guangdong VTR Bio-Tech (300381.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved a revenue of 6...
Guangdong VTR Bio-Tech (300381.SZ): net income in the third quarter was 1.0152 million yuan, a year-on-year decrease of 79.64%.
Guangdong VTR Bio-Tech (300381.SZ) announced its third quarter report for 2024 on October 22nd. During the reporting period, the revenue was 0.211 billion yuan, a decrease of 3.52% year-on-year. The net income attributable to shareholders of the listed company was 1.0152 million yuan, a decrease of 79.64% year-on-year. The net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was -4.832 million yuan. Basic earnings per share were 0.0021 yuan.
Guangdong VTR Bio-Tech Co., Ltd. (SZSE:300381) Held Back By Insufficient Growth Even After Shares Climb 41%
Shareholders 32% Loss in Guangdong VTR Bio-Tech (SZSE:300381) Partly Attributable to the Company's Decline in Earnings Over Past Three Years